Cardiac Urea Cycle Activation by Time-Restricted Feeding Protects Against Pressure Overload-Induced Heart Failure

Yanzhen Tan1,2, Min Li1, Han Li1

  • 1Key Laboratory of Ministry of Education, School of Aerospace Medicine, Fourth Military Medical University, Xi'an, 710032, China.

Insights

Time-restricted feeding (TRF) protects against heart failure by increasing circulating amino acids and activating the cardiac urea cycle. This pathway, involving argininosuccinate lyase (ASL), is crucial for heart health and impaired in human heart failure.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Regulation
  • Nutritional Science

Background:

  • Heart failure is a major global health concern requiring new treatments.
  • Time-restricted feeding (TRF) shows promise for preventing and treating heart disease.
  • The role of amino acids and the urea cycle in cardiac function needs further elucidation.

Purpose of the Study:

  • To investigate the cardioprotective effects of TRF in heart failure.
  • To explore the mechanisms underlying TRF's benefits, focusing on amino acid metabolism and the urea cycle.
  • To assess the relevance of these findings in human patients with cardiac dysfunction.

Main Methods:

  • Utilized mouse models of heart failure with different stages.
  • Performed metabolomic profiling of circulating and cardiac metabolites.
  • Conducted cardiac-specific argininosuccinate lyase (ASL) knockout studies.
  • Analyzed arteriovenous gradients of metabolites in human hearts.

Main Results:

  • TRF conferred protection against heart failure in mice.
  • TRF increased circulating amino acids and activated cardiac amino acid utilization and the urea cycle via ASL.
  • Cardiac ASL upregulation by TRF is mediated by transcription factor Yin Yang 1.
  • Impaired amino acid utilization and urea cycle activity were observed in human hearts with reduced function.

Conclusions:

  • TRF is a potential therapeutic strategy for heart failure.
  • The cardiac urea cycle, particularly ASL, plays a vital role in TRF-mediated cardioprotection.
  • Restoring amino acid metabolism and urea cycle function may be beneficial for patients with heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1